

1 THC exposure is reflected in the microstructure of  
2 the cerebral cortex and amygdala of young adults

3  
4 Ryan P. Cabeen  
5 Laboratory of Neuro Imaging  
6 USC Stevens Neuroimaging and Informatics Institute  
7 Keck School of Medicine of USC  
8 University of Southern California  
9 Los Angeles, CA, USA  
10 rcabeen@loni.usc.edu

11  
12 John M. Allman  
13 Division of Biology  
14 California Institute of Technology  
15 Pasadena, CA, USA  
16 cebus@caltech.edu

17  
18 Arthur W. Toga  
19 Laboratory of Neuro Imaging  
20 USC Stevens Neuroimaging and Informatics Institute  
21 Keck School of Medicine of USC  
22 University of Southern California  
23 Los Angeles, CA, USA  
24 toga@loni.usc.edu

25  
26 February 24, 2020

## Abstract

The endocannabinoid system serves a critical role in homeostatic regulation through its influence on processes underlying appetite, pain, reward, and stress, and cannabis has long been used for the related modulatory effects it provides through tetrahydrocannabinol (THC). We investigated how THC exposure relates to tissue microstructure of the cerebral cortex and subcortical nuclei using computational modeling of diffusion magnetic resonance imaging data in a large cohort of young adults from the Human Connectome Project. We report strong associations between biospecimen-defined THC exposure and microstructure parameters in discrete gray matter brain areas, including frontoinsular cortex, ventromedial prefrontal cortex, and the lateral amygdala subfields, with independent effects in behavioral measures of memory performance, negative intrusive thinking, and paternal substance abuse. These results shed new light on the relationship between THC exposure and microstructure variation in brain areas related to salience processing, emotion regulation, and decision making. The absence of effects in some other cannabinoid-receptor-rich brain areas prompts the consideration of cellular and molecular mechanisms that we discuss. Further studies are needed to characterize the nature of these effects across the lifespan and to investigate the mechanistic neurobiological factors connecting THC exposure and microstructural parameters.

**Keywords:** THC; microstructure; diffusion MRI; cerebral cortex; amygdala

The endocannabinoid system is known to serve a critical homeostatic role in the central nervous system (Volkow et al., 2017; Silvestri and Di Marzo, 2013), in which it modulates appetite, pain, stress, and reward processing (Tarragon and Moreno, 2017; Freund et al., 2003; Mackie and Stella, 2006); yet, there remain open questions regarding its relation to behavior and response to exogenous cannabinoids. Molecular biological studies have shown that it functions through retrograde signaling of cannabinoid neurotransmitters (Kreitzer and Regehr, 2002; Hua et al., 2016; Devane et al., 1992) that modulate cell function by binding endocannabinoid receptors (Hua et al., 2016; Devane et al., 1992), which are found throughout the brains of mammals with varied density based on cell type and brain area (Herkenham et al., 1990; Devane et al., 1988; Glass et al., 1997). Cannabis is a plant whose consumption produces modulatory effects on the endocannabinoid system, making it a fixture of human societies spanning an array of uses and contexts (National Academies of Sciences, Engineering, and Medicine and others, 2017; Long et al., 2017; Grotenhermen, 2003). In particular, it produces psychotropic effects such as euphoria and relaxation that are considered driving factors in recreational usage (Green et al., 2003; van Hell et al., 2011). Until recently, there have been restricted avenues for legal cannabis use and research, but regulatory changes have expanded what cannabis products are available, the ways in which the public consumes them, and the

65 possibilities for research (Haney and Hill, 2018; Hasin, 2017). This presents a need for  
66 better understanding the specific ways that cannabis affects the brain and the consequent  
67 changes in behavior (Murray et al., 2007; Hall and Degenhardt, 2009).

68 Epidemiological and pharmacological studies have shed light on the effects of cannabis,  
69 indicating both therapeutic applications and health risks associated with its use (National  
70 Academies of Sciences, Engineering, and Medicine and others, 2017; Hall, 2015; Volkow  
71 et al., 2014). While cannabis has many neuropharmacologically active agents, tetrahydro-  
72 cannabinol (THC) is the primary psychoactive compound that motivates its recreational  
73 usage (Andre et al., 2016; ElSohly et al., 2014). It acts as a partial agonist on type 1  
74 cannabinoid receptor (CB1) (Grotenhermen, 2003), in which it modulates the function of  
75 the endocannabinoid system to alter mood, perception and appetite to produce a char-  
76 acteristic relaxed or euphoric state (Agrawal et al., 2014; Mattes et al., 1994) with acute  
77 side effects including reduced short-term memory, impaired motor skills, and heightened  
78 anxiety and paranoia (Gonzalez, 2007). Studies of long term neurological effects of THC  
79 exposure have shown reversible downregulation of CB1 receptors (Hirvonen et al., 2012),  
80 impaired cognition (Broyd et al., 2016; Batalla et al., 2013b), and increased risk of psy-  
81 chosis, particularly in adolescence (Marconi et al., 2016; Large et al., 2011; Moore et al.,  
82 2007; Andrade, 2016). In contrast, studies of therapeutic applications of THC have found  
83 substantial support for its use in treating chronic pain (Smith et al., 2015; Andraea et al.,  
84 2015) and chemo-therapy induced nausea and vomiting (Grotenhermen and Müller-Vahl,  
85 2012; Whiting et al., 2015; Smith et al., 2015).

86 Magnetic resonance imaging (MRI) has emerged as a useful tool for delineating the  
87 structural and functional changes associated with THC exposure, and these findings have  
88 been comprehensively reviewed (Bloomfield et al., 2018; Lisdahl et al., 2014; Batalla et al.,  
89 2013a; Quickfall and Crockford, 2006). Cerebral blood flow (CBF) imaging studies have  
90 identified changes in prefrontal and insular areas (Mathew et al., 1997; van Hell et al.,  
91 2011), and functional MRI (fMRI) studies have expanded this picture to identify network-  
92 level and task-dependent changes in brain connectivity during THC exposure. Several  
93 studies have shown disruptions in salience processing, i.e. changes in connectivity of in-  
94 sular and anterior cingulate regions with other brain areas (Bhattacharyya et al., 2015;  
95 Wetherill et al., 2015; Battistella et al., 2013; Hester et al., 2009; Bhattacharyya et al.,  
96 2012). There is further evidence of functional alterations of fear and emotion processing  
97 in areas such as the amygdala (Phan et al., 2008; Colizzi et al., 2018; Heitzeg et al., 2015),  
98 and task-specific findings showing effects related to motor inhibition (Borgwardt et al.,  
99 2009), reward anticipation (Nestor et al., 2010), spatial working memory (Schweinsburg  
100 et al., 2010) and cognitive control (Harding et al., 2012). In contrast, structural neu-  
101 roimaging has provided a complementary picture of associations of THC exposure with  
102 brain morphology and tissue properties of gray and white matter. Morphometric studies  
103 have found effects in subcortical gray matter structures, such as the nucleus accumbens,

104 amygdala, and hippocampus (Lorenzetti et al., 2019; Gilman et al., 2014; Owens et al.,  
105 2019), as well as cortical effects in gray matter density in prefrontal areas, insular cortex,  
106 and the cerebellum (Medina et al., 2010; Churchwell et al., 2010; Battistella et al., 2014).  
107 Similar to functional studies, gray matter effects have been detected that are specifically  
108 related to psychosis (Schnell et al., 2012). More refined analysis has further shown cor-  
109 tical thinning in prefrontal and insular cortex (Lopez-Larson et al., 2011; Jacobus et al.,  
110 2015; Shollenbarger et al., 2015). Diffusion imaging has revealed white matter effects  
111 (Becker et al., 2015; Yücel et al., 2010; Jacobus et al., 2013; Orr et al., 2016), with con-  
112 sistent results in the corpus callosum (Arnone et al., 2008; Zalesky et al., 2012; Rigucci  
113 et al., 2015), in adolescence (Ashtari et al., 2009), and in relation to impulsivity (Gruber  
114 et al., 2011). Together, these imaging studies provide substantial support for numerous  
115 and persistent changes in the brain function and structure related to THC exposure;  
116 however, there remain open questions regarding the neuroanatomical features related to  
117 tissue organization that are involved.

118 In this study, we investigated how microstructure organization relates to THC expo-  
119 sure, focusing on the cerebral cortex and subcortical nuclei involved in decision-making  
120 and emotion regulation. While gray matter morphology and volumetry approaches are  
121 powerful tools, they provide measures of neuroanatomy that are relatively coarse-grain  
122 and non-specific to the underlying tissue organization. Our experiments use recent ad-  
123 vances in multi-shell diffusion MRI and computational modeling techniques to probe  
124 aspects of the organizational properties of tissue microstructure that have been previ-  
125 ously unexplored in relation to THC exposure. Our analysis is distinguished from past  
126 diffusion MRI studies of THC exposure that focused on white matter tissue properties;  
127 in contrast, we examined gray matter imaging parameters, which may capture distinct  
128 microstructural features of neurites and glial cells. Our experiments specifically char-  
129 acterized the relationship between gray matter microstructure imaging parameters and  
130 biospecimen-defined THC exposure in a large cohort of typical young adults recruited and  
131 scanned cross-sectionally as part of the Human Connectome Project, using a multi-modal  
132 and computational approach to derive quantitative indices of tissue microstructure. Our  
133 analysis primarily examined fronto-insular cortex and subcortical brain areas (nucleus  
134 accumbens, caudate, putamen, substantia nigra, hippocampus, hypothalamus, and pe-  
135 riaqueductal gray), and in a subsequent analysis, we expanded the analysis across the  
136 cerebral cortex to assess the anatomical specificity of our results. We report differences  
137 in an index of neurite orientation dispersion (ODI) that are localized in bilateral fron-  
138 toinsular and ventromedial prefrontal cortex and the lateral subfields of the amygdala,  
139 with analogous findings shown with fractional anisotropy using diffusion tensor imaging.  
140 Our analysis further investigated the connection between these findings and individual  
141 behavioral measures, showing independent effects in memory performance, negative intru-  
142 sive thinking, and paternal substance abuse. We discuss the relevance of these findings

143 and the connection of THC exposure with brain areas underlying salience processing,  
144 emotion regulation, and decision making. We did not detect microstructural effects in  
145 all cannabinoid-receptor-rich brain areas, which motivates several hypotheses concerning  
146 potential molecular and cellular mechanisms that we propose to potentially explain our  
147 findings.

## 148 **Materials and Methods**

### 149 **Participants and Datasets**

150 Data were acquired from participants as part of the Human Connectome Project (HCP).  
151 We obtained T<sub>1</sub>-weighted (T1wMRI) and diffusion-weighted MRI (dwMRI) data, and  
152 included 781 participants with scans that pass quality control and completed image pro-  
153 cessing. Following institutional ethics review, we also analyzed demographic and be-  
154 havioral data from the restricted data release, which included age, gender, self-reported  
155 substance use, and self-reported family history of substance abuse. Biospecimen-defined  
156 THC exposure was assessed with a urine screen (Alere iScreen 6-panel urine drug test dip  
157 card; DOA164-551), and 85 participants were included that tested positive for THC ex-  
158 posure, as determined as per the manufacturer’s criterion cut-off of 50 ng/mL of the THC  
159 metabolite 11-nor- $\Delta$ 9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH). We also ex-  
160 amined an additional self-reported total number of cannabis uses, which consisted of  
161 the the following levels: no use = 0; 1-5 uses = 1; 6-10 uses = 2; 11-101 uses = 3;  
162 101-999 uses = 4; 1000 or more uses = 5. Participants completed a set of instruments  
163 from the Achenbach System of Empirically Based Assessment (ASEBA) (Achenbach and  
164 Rescorla, 2003), and from this, we retained the adult self-report thought problems scale  
165 (Abdellaoui et al., 2012). We used this scale to operationalize a summary measure of  
166 negative intrusive thinking, as the questionnaire includes self-reported measures of hallu-  
167 cinations, self-destructive thoughts, repetitive behavior, and other factors that negatively  
168 impact daily life. Working memory was assessed using the NIH Toolbox, and our analysis  
169 examined the overall accuracy across all conditions.

### 170 **Image Acquisition and Preprocessing**

171 T1wMRI and dwMRI data from the HCP was collected on a Connectome Siemens 3 Tesla  
172 Skyra scanner using a 32-channel head coil (Glasser et al., 2013; Van Essen et al., 2013).  
173 The T1wMRIs were acquired using a 3D MPRAGE sequence with 0.7 mm isotropic  
174 resolution (FOV = 224 mm, matrix = 320, 256 sagittal slices in a single slab), repetition  
175 time (TR) = 2400 ms, echo time (TE) = 2.14 ms, inversion time (TI) = 1000 ms, flip  
176 angle = 8°, bandwidth = 210 Hz per pixel, echo spacing = 7.6 ms, and phase encoding

177 undersampling factor GRAPPA = 2.10%. dwMRIs were collected with a single-shot 2D  
178 spin-echo EPI acquisition with a multi-band factor of 3, 1.25 mm isotropic voxels with  
179 FOV PE by Readout = 210 x 180; matrix size PE by Readout = 144 x 168; 111 interleaved  
180 slices without gap; left-right and right-left phase encoding; flip angles = 78° and 160°.  
181 For each phase encoding direction, the diffusion sampling scheme consisted of 18 baseline  
182 scans and 270 diffusion-weighted scans acquired using single diffusion encoding across 3  
183 shells with  $b = 1000, 2000, \text{ and } 3000 \text{ s/mm}^2$ ; all dwMRI scans had TE = 89 ms and TR  
184 = 5.5 s. Each shell included 192 data points representing 90 diffusion gradient directions  
185 and six  $b = 0$  shells acquired twice resulting in 270 non-collinear directions for each PE.  
186 Total acquisition time was approximately 54 min (6 segments of 9 min each). dwMRI  
187 data was preprocessed with the HCP workflow (Sotiropoulos et al., 2013). This included  
188 a sophisticated approach for correction of artifact due to motion and eddy-current and  
189 susceptibility induced geometric distortion. Using an additional set of diffusion MRI scans  
190 collected with reversed phase encoding, this scheme estimates and corrects for the off-  
191 resonance field and subject head motion using a Gaussian process framework for robust  
192 non-parameteric interpolation of the dwMRI signal.

## 193 Image Analysis




Figure 1: An overview of the anatomical modeling components used in our analysis. Panel A shows the manually drawn fronto-insular cortex mask used in the region of interest analysis, and panel B shows amygdala subfields that were obtained from the Caltech Amygdala Atlas and included as well (T1wMRI shown in background). Panel C illustrates the cortical surface analysis, in which the pial boundary (cyan) and white matter boundary (yellow) were used to estimate cortical microstructure (ODI shown in background) in brain areas from the HCP multimodal parcellation.

194 The HCP data was subsequently analyzed using the LONI Pipeline (Dinov et al., 2009)  
195 to obtain microstructure parameters characterizing the cerebral cortex and subcortical  
196 nuclei. The workflow was implemented with the Quantitative Imaging Toolkit (QIT)

197 (Cabeen et al., 2018), Freesurfer (Fischl, 2012), FSL (Jenkinson et al., 2012), ANTs  
198 (Avants et al., 2008), and DTI-TK (Zhang et al., 2006). The main components are  
199 illustrated in Figure 1 and described as follows.

200 The dwMRI data were denoised using a non-local means filter and microstructure pa-  
201 rameters were obtained using two multi-shell modeling approaches. First, we performed  
202 neurite orientation dispersion and density imaging (NODDI) (Zhang et al., 2012) and  
203 estimated its parameters using a non-linear fitting approach accelerated using the spheri-  
204 cal mean technique (Cabeen et al., 2019), resulting in volumetric maps of the orientation  
205 dispersion index (ODI), neurite density index (NDI), and isotropic volume fraction (ISO).  
206 Because our experiments look specifically at gray matter, we used a parallel diffusivity of  
207  $1.1 \times 10^{-3} \text{ mm}^2/\text{s}$ , which is an optimized value obtained from previous work (Fukutomi  
208 et al., 2018). NDI is meant to depict the proportion of neurite volume relative to the  
209 total cellular volume, while ODI is meant to separately depict neurite orientational het-  
210 erogeneity. We also estimated diffusion tensor imaging (DTI) (Basser and Jones, 2002)  
211 parameters using weighted linear least squares fitting with free-water elimination with a  
212 fixed diffusivity of  $3.0 \times 10^{-3} \text{ mm}^2/\text{s}$  in the isotropic compartment (Hoy et al., 2014),  
213 resulting in volumetric maps of fractional anisotropy (FA) and mean diffusivity (MD). We  
214 then created a population-averaged dataset from 88 scans from the test-retest portion of  
215 the HCP dataset. We used the tensor-based deformable registration and spatial normal-  
216 ization pipeline implemented in DTI-TK (Zhang et al., 2007) to produce the population  
217 averaged DTI, NODDI, and T1wMRI datasets that were aligned to the IIT template  
218 (Zhang et al., 2011). Subject data from all participants was then spatially normalized to  
219 the template and the deformable registration maps were retained for each individual.

220 Our initial goal was to investigate gray matter microstructure parameters in frontoin-  
221 sular cortex (FIC) and related structures involved with decision-making and emotion  
222 regulation using a region-of-interest (ROI) approach. We subsequently expanded our  
223 analysis to include cannabinoid-receptor-rich brain areas. Guided by the definition from  
224 Allman et al. (2010), we first manually delineated ROIs on coronal slices of the tem-  
225 plate for left and right FIC using QIT and co-registered these in subject native space  
226 and computed region-averaged parameters. The other additional structures we examined  
227 included: the nucleus accumbens, caudate, putamen, substantia nigra (separate com-  
228 pact and reticular parts), hippocampus, hypothalamus, and periaqueductal gray. ROIs  
229 were obtained from the Caltech Subcortical and Amygdala Atlases (Pauli et al., 2018;  
230 Tyszka and Pauli, 2016), and the remainder were manually drawn on the population av-  
231 erage. The Caltech atlas data was aligned to our population average T1wMRI map using  
232 ANTs diffeomorphic registration, and the amygdala atlas includes ten subfields, which  
233 are described in detail in the publication associated with the atlas.

234 In a subsequent analysis, we also investigated microstructure properties across the  
235 entire cerebral cortex, with the goal of determining the anatomical specificity of the

236 fronto-insular findings in the ROI analysis. We processed T1wMRI data using Freesurfer  
237 to create 3D cortical models, and the cortical models were linearly aligned with the  
238 diffusion data using FSL FLIRT with the mutual information cost function. To estimate  
239 cortical microstructure, we took a similar approach to Fukutomi et al. (2018) and refined  
240 the alignment of the cortical surface to better match the tissue boundaries in the diffusion  
241 scan, which may retain subtle geometric distortions not found in the T1wMRI. Briefly,  
242 for each subject, we computed the weighted average microstructure parameters in each  
243 vertex of the Freesurfer cortical surface, which was aligned to native diffusion space. The  
244 surface-based parameter average was computed in two stages. In the first stage, the  
245 midpoint between the pial and white matter surfaces was computed and 15 sampling  
246 points were equally spaced between them, with an additional 2 mm buffer on either  
247 side. For a given microstructure parameter, the values were measured at each of the  
248 sampling point and subsequently inversely weighted by their distance to the midpoint  
249 and the by tissue MD, with the goal of avoiding contamination by white matter and  
250 CSF. In the second stage, the mean and standard deviation were computed and outlier  
251 values were detected and excluded using a z-score threshold of 3.0; finally, the average  
252 value was found from the remaining points. We then summarized the microstructure  
253 parameters in the regions defined by the HCP multi-modal parcellation (HCP-MMP-  
254 1.0), which includes 180 cytoarchitectonically defined parcels in each hemisphere (Glasser  
255 et al., 2016). The HCP-MMP-1.0 region most closely aligned with the manually drawn  
256 fronto-insular ROI was agranular anterior insular cortex (AAIC). For each subject, we  
257 also created a composite ventro-medial prefrontal cortex (vmPFC) region by averaging  
258 the microstructure parameters from Brodmann areas p32, s32, a24, and 10r, and we  
259 computed interhemispheric averages of the AAIC and vmPFC measures.

## 260 **Statistical Analysis**

261 We first estimated multiple linear regression models to relate microstructure to the subject  
262 variables with covariates including: age, gender, body mass index (BMI), intra-cranial  
263 volume (ICV), and whether the subject was a daily smoker or drinker. All continuous  
264 model parameters were normalized to zero-mean and unit-variance to allow their regres-  
265 sion coefficients to be reported in standardized units. We excluded outliers using Tukey’s  
266 procedure, in which high and low cutoffs were determined by 1.5 times the inter-quartile  
267 range beyond the low and high quartiles, computed using the entire cohort. Covariates  
268 were added using forward stepwise model selection; after which, the variable-of-interest,  
269 e.g. THC exposure, was included in the model. We used the Bayesian Information Cri-  
270 teria (BIC) for model selection, a statistical measure that balances model complexity  
271 and goodness-of-fit (Vrieze, 2012). We retained the  $R^2$  coefficient of determination of  
272 the model, and the statistical outcomes of each subject variable, including the regression

273 coefficient, t-value, standard error, and p-value. To measure the support for including  
274 THC exposure in models explaining microstructure variation, we also retained the change  
275 in adjusted  $R^2$  and change in BIC between models with and without THC exposure. For  
276 data from the surface-based analysis with the HCP-MMP regions, we corrected for mul-  
277 tiple comparisons using the Benjamini-Hochberg procedure to control the false discovery  
278 rate (FDR), that is, the expected proportion of type I errors (Benjamini and Hochberg,  
279 1995). We then created 3D cortical surface visualizations showing the resulting FDR  
280 q-values across the HCP-MMP regions.

281 Subsequent to our primary analysis, we also examined the relationship between mi-  
282 crostructure and demographic and behavioral measures. Besides demographic variables,  
283 we also analyzed measures of memory performance, negative intrusive thinking, and pa-  
284 ternal substance abuse, which are factors related to THC exposure that we identified  
285 empirically from a preliminary analysis of the data. Our goal was then to assess their  
286 connection with both THC and gray matter microstructure. We estimated a multiple  
287 linear regression model relating microstructure variation to the combination of these  
288 measures. To reduce the complexity of the analysis, we summarized the microstructure  
289 parameters from FIC, AAIC, vmPFC, and the amygdala with a single general factor,  
290 by performing principal component analysis and extracting the scores of the first com-  
291 ponent. This general factor was used as a dependent variable in the regression model  
292 that included THC exposure, age, gender, BMI, smoking, drinking, memory, negative  
293 intrusive thinking, and paternal substance abuse as covariates.

294 Finally, we compared THC exposure as assessed from the urine screen with the self-  
295 reported total cannabis usage. We estimated linear regression models to test both the  
296 agreement of self-reported usage with THC test results and the association of self-reported  
297 results with microstructure parameters identified in the previous analysis. This was  
298 included to both confirm the validity of the THC test and to characterize dose-dependent  
299 effects, which are not otherwise available from the THC screen.

300 Our statistical analysis was implemented using R 3.3.3, plots were created using ggplot  
301 3.2.1 (Wickham, 2017), and tables were created using stargazer 5.2.2 (Hlavac, 2013). 3D  
302 visualizations of statistical maps overlaid on brain anatomy were created using QIT.

## 303 Results

304 Our primary analysis showed significant and strong associations between THC exposure  
305 and NODDI ODI in frontoinsular cortex (std.  $\beta = 0.501$ ,  $p = 2.9 \times 10^{-5}$ ) and three  
306 amygdala subfields comprising the lateral portion: the lateral basolateral nucleus (BLN-  
307 La) (std.  $\beta = 0.447$ ,  $p = 1.8 \times 10^{-4}$ ), the combined amygdala and amygdalostriatal  
308 transition areas (ATA-ASTA) (std.  $\beta = 0.280$ ,  $p = 1.7 \times 10^{-3}$ ), and the intercalated  
309 nucleus (INA) (std.  $\beta = 0.362$ ,  $p = 2.3 \times 10^{-3}$ ). The data are shown in Figures 3A and

310 3B and regression results are summarized in Table 1. The statistical results are visualized  
 311 on 3D models of the amygdala subfields in Figure 2B. No significant associations were  
 312 found with other subcortical nuclei or with NODDI NDI. DTI FA showed similar effects  
 313 as NODDI ODI, though with smaller effect sizes and larger  $p$ -values.

Region	$\Delta\text{BIC}$	$R^2$	$R^2_{adj}$	$\Delta R^2_{adj}$	std. $\beta$	<i>s.e.</i>	$p$ -value
Frontoinsular	11.0	0.073	0.069	0.020	0.501	(0.119)	<b><math>2.9 \times 10^{-5}</math></b>
Anterior insular	8.0	0.111	0.106	0.016	0.443	(0.116)	<b><math>1.4 \times 10^{-4}</math></b>
Ventromedial PFC	5.7	0.106	0.100	0.014	0.409	(0.116)	<b><math>4.6 \times 10^{-4}</math></b>
Amygdala BLN-La	7.4	0.062	0.057	0.016	0.447	(0.119)	<b><math>1.8 \times 10^{-4}</math></b>
Amygdala INA	2.7	0.043	0.038	0.010	0.362	(0.119)	<b><math>2.3 \times 10^{-3}</math></b>
Amygdala ATA-ASTA	-0.9	0.073	0.068	0.006	0.280	(0.117)	<b><math>1.7 \times 10^{-2}</math></b>
General factor	18.0	0.124	0.119	0.027	0.573	(0.115)	<b><math>7.7 \times 10^{-7}</math></b>

Table 1: Significant statistical associations between THC exposure and ODI. Each row shows THC effects from a multiple linear regression model that included age, sex, body mass index, intracranial volume, smoking, and drinking as covariates. Data was centered and scaled to zero-mean and unit variance before modeling to standardize  $\beta$  coefficients. For each parameter, models were fit with and without THC exposure (as measured from a urine drug screen), and the change in Bayesian Information Criteria (BIC) and  $R^2_{adj}$  was computed to further quantify the contribution of THC to the model. The results show the strongest effects were in fronto-insular cortex (FIC, AAIC) and the lateral portion of the basolateral amygdala (BLN-La). All results were from left-right averaged parameters. Other statistical results can be found in the supplementary material.

314 In our surface-based analysis of the cerebral cortex, we found significant associations  
 315 between THC exposure and NODDI ODI in agranular anterior insular cortex (AAIC),  
 316 several regions of comprising ventromedial cortex (Brodmann areas p32, s32, a24, and  
 317 10r), and several others weaker effects shown in Figure 2A. DTI FA showed similar results  
 318 but with smaller effect sizes, and they can be found in the supplemental material. No  
 319 significant associations were found with NODDI NDI. Because they exhibited bilateral  
 320 symmetry, we focused on effects in agranular anterior insular and ventro-medial prefrontal  
 321 cortices, as illustrated in Figure 2A. Statistical analysis of the interhemispheric averages  
 322 showed the strongest in frontoinsular cortex (std.  $\beta = 0.501$ ,  $p = 2.9 \times 10^{-5}$ ), vmPFC  
 323 (std.  $\beta = 0.409$ ,  $p = 4.6 \times 10^{-4}$ ), and BLN-La of the amygdala (std.  $\beta = 0.447$ ,  $p = 1.8$   
 324  $\times 10^{-4}$ ). The AAIC overlapped substantially with the manually drawn FIC mask, but the  
 325 effect sizes in AAIC were smaller than the those from FIC. The composite vmPFC region  
 326 showed a stronger effect than the individual regions that comprised it, and the general  
 327 factor showed the greater effect overall (std.  $\beta = 0.573$ ,  $p = 7.7 \times 10^{-7}$ ). The data are  
 328 shown in Figure 3A and regression results are summarized in Table 1.

329 Regarding the model evaluation, FIC showed the strongest support for including THC  
 330 exposure in the model ( $\Delta\text{BIC} = 11.0$ ), and at the other extreme, the BIC suggested that  
 331 in ATA-ASTA, the inclusion of THC exposure did not improve the model ( $\Delta\text{BIC} <$   
 332  $0$ ). The other areas showed positive (INA, vmPFC) to strong (AAIC, BLN-La) support




Figure 2: Visualizations showing anatomical areas with significant statistical associations between the ODI and THC exposure. Panel A shows results from the cortical surface analysis, where there were strong bilateral effects in agranular anterior insular cortex (AAIC) and ventromedial prefrontal cortex (VMPFC). Panel B shows results from the amygdala subfield analysis, where three areas comprising the lateral portion were identified.




Figure 3: Plots showing the relationship between the orientation dispersion index and THC exposure. Panels A and B show associations between ODI and drug test results in cortical and amygdala gray matter. The results indicated THC exposure is associated with higher orientation dispersion. Panel C shows analogous results with self-reported cannabis use. The first plot shows strong agreement between drug test results and self-reported use, and the second two plots show dose-dependency and ODI, wherein ODI has greater differences at the higher end of the scale. The plots include dots representing individual participants, and boxplots are overlaid to show the median and quartiles.

333 for THC exposure improving the model (Kass and Raftery, 1995). In comparing the  
 334 models from different diffusion parameters, the  $R^2$  coefficients of NODDI ODI models  
 335 were generally higher than those from DTI FA.


Table 2: Significant statistical associations between demographic and behavioral parameters and a general factor of orientation dispersion index values. The dependent variable was defined by the principal component scores computed to summarize NODDI ODI values in FIC, AAIC, vmPFC, BLN-La, ATA-ASTA, and INA. Each row shows a different variable included in a single multiple linear regression model, and the columns list statistical parameters associated with them. The results show that gender, body mass index (BMI), memory performance, paternal substance abuse, and disordered thought contribute to variation in the ODI general factor; however, with these covariates, THC retains a strong significant relationship with ODI indicating an independent contribution to variation in microstructure.

Variable	<i>std.</i> $\beta$	<i>s.e.</i>	<i>t</i> -stat.	<i>p</i> -value
THC positive	0.417	(0.115)	3.7	<b>2.8 x 10<sup>-4</sup></b>
Gender	0.574	(0.088)	6.5	<b>9.9 x 10<sup>-11</sup></b>
Age	0.057	(0.035)	1.7	0.10
Body Mass Index	0.021	(0.006)	3.2	<b>0.014</b>
Memory	-0.102	(0.035)	-2.9	<b>0.042</b>
Negative Intrusive Thinking	0.137	(0.035)	4.0	<b>7.8 x 10<sup>-5</sup></b>
Paternal Substance Abuse	0.214	(0.097)	2.2	<b>0.028</b>
Daily Smoker	0.011	(0.015)	0.7	0.47
Daily Drinker	0.034	(0.019)	1.8	0.077
Intracranial Volume	-0.053	(0.044)	-1.2	0.22
Observations	768			
R <sup>2</sup>	0.181			
Adjusted R <sup>2</sup>	0.170			

336 Our analysis of behavioral parameters showed significant associations of the mi-  
 337 crostructure general factor score with: gender ( $\beta = 0.574$ ,  $p = 2.8 \times 10^{-4}$ ), BMI (std.  
 338  $\beta = 0.057$ ,  $p = 0.014$ ), memory (std.  $\beta = -0.102$ ,  $p = 0.042$ ), paternal substance abuse  
 339 ( $\beta = 0.214$ ,  $p = 0.028$ ), and negative intrusive thinking (std.  $\beta = 0.137$ ,  $p = 7.8 \times$   
 340  $10^{-5}$ ). Furthermore, the effect of THC exposure retained significance and a large effect  
 341 size when included with these covariates (std.  $\beta = 0.417$ ,  $p = 2.8 \times 10^{-4}$ ), and the total  
 342 variance explained by the model was  $R^2 = 0.181$ . The data are shown in Figure 4 and  
 343 the regression results are summarized in Table 2.

344 The comparison of self-reported cannabis use with the THC urine screen showed a  
 345 strong correlation, indicating a substantial agreement between the two measures. Figure  
 346 3C shows plots of how the self-reported cannabis use scores relate to observed microstruc-  
 347 ture parameters. Multiple linear regression models showed similar significant associations  
 348 as the urine screen; however, the models with self-reported cannabis use had smaller ef-

### A. A General Factor of Tissue Microstructure and Demographic Parameters



### B. A General Factor of Tissue Microstructure and Behavioral Characteristics




Figure 4: Plots showing the relationship between demographic and behavioral parameters and a general factor of ODI microstructure. The general factor was derived through principal component analysis of ODI values in FIC, AAIC, VMPFC, BLN-La, ATA-ASTA, and INA. The top row shows the relationship between the ODI general factor and THC, gender, and body mass index (BMI). ODI shows a positive trend with THC exposure, male subjects, and higher BMI. The second row shows the relationship between the ODI general factor and memory performance, negative intrusive thinking, and paternal substance abuse. The results indicates that poorer memory performance is associated high ODI, as is a higher score on the thought problems scale and the paternal substance abuse. The plots include dots representing individual participants, and either boxplots or regression lines are overlaid to show the median and quartiles.

349 fect sizes and larger p-values than those from the urine screen. The largest individual  
350 effects with self-reported cannabis use were in FIC (std.  $\beta = 0.093$ ,  $p = 9.1 \times 10^{-6}$ ) and  
351 amygdala BLN-La (std.  $\beta = 0.103$ ,  $p = 1.07 \times 10^{-6}$ ), and the general factor showed the  
352 strongest effect overall (std.  $\beta = 0.122$ ,  $p = 5.86 \times 10^{-9}$ ). Figure 3C shows plots of how  
353 the self-reported cannabis usage scores relate to observed microstructure parameters, and  
354 the non-parametric local regression plot indicates the change in ODI is principally at the  
355 high end of the scale, where total reported uses exceeds 1000 uses.

356 A comprehensive summary of our experiments and results can be found in the sup-  
357 plementary material.

## 358 Discussion

359 The present study combined high-quality multimodal neuroimaging data with advanced  
360 computational modeling approaches to characterize microstructure of the cerebral cor-  
361 tex and subcortical nuclei and how it relates to THC exposure. By analyzing the large  
362 cohort provided by the HCP, we quantitatively characterized microstructure variation in  
363 relation to biospecimen-defined THC exposure as it occurs in a typical non-clinical popu-  
364 lation. In particular, our analysis demonstrated that THC exposure is strongly associated  
365 with differential microstructure organization in the cerebral cortex and amygdala, and  
366 furthermore, that they are linked with independent effects in behavioral measures of  
367 memory performance, negative intrusive thinking, and paternal substance abuse. Using  
368 computational anatomical modeling, our analysis enabled the localization of these ef-  
369 fects in frontoinsular cortex, ventromedial prefrontal cortex, and lateral subfields of the  
370 amygdala. A comparison of diffusion parameters showed that the ODI had greater sen-  
371 sitivity to these effects, while DTI fractional isotropy detected them to a lesser extent.  
372 We focused on the urine drug screen as a primary indicator of THC exposure, and our  
373 statistical comparison of the drug test results with self-reported cannabis use suggested a  
374 close relationship. The results also provide some support for a dose-dependent effect, as  
375 greater self-reported use was also associated with higher ODI. However, the THC urine  
376 screen proved the most sensitive for identifying brain associations with microstructure,  
377 perhaps because it affords a lower chance for reporting errors from participants. In ad-  
378 dition, drug screens have been found to have a dose-dependency of their own, in which  
379 heavy users have a longer time period in which they test positive (Moeller et al., 2017),  
380 a factor which may bias the THC positive participant pool towards those with higher  
381 levels of exposure. Furthermore, our results suggest that the observed effects are distinct  
382 from other substance use, including alcohol and nicotine.

383 Our findings support an emerging picture of the important link between frontoinsular  
384 cortex, prefrontal cortex, and the amygdala and THC exposure, which is supported by  
385 past neuroimaging looking at cerebral blood flow, functional activation, and morphome-

386 try with THC exposure. Several previous studies have specifically looked at brain changes  
387 with THC exposure in the HCP dataset, as we did in our study, and they found related  
388 changes in neuropsychological performance (Petker et al., 2019), poorer working memory  
389 with associated functional changes (Lorenzetti et al., 2019; Gilman et al., 2014; Owens  
390 et al., 2019), reduced amygdala and hippocampal volume (Pagliaccio et al., 2015; Owens  
391 et al., 2019), reduced segregation between cognition and emotional function processing  
392 (Manza et al., 2019), and changes in white matter integrity (Orr et al., 2016). However,  
393 because no studies to date have yet explored the relationship between THC and gray  
394 matter microstructure, the present studies represents a novel perspective on the struc-  
395 tural organization of brain microanatomy in relation to THC. Specifically, we showed  
396 evidence that discrete brain areas are related to THC exposure, and furthermore, we  
397 found that the greatest sensitivity was obtained when deriving a single general factor  
398 from a linear combination of these areas. These findings raise several issues considering  
399 the endocannabinoid system and how exogenous THC exposure is perhaps related to  
400 measurable changes in tissue microstructure.

401 We can first consider our findings at a systems level, that is, related to functional as-  
402 pects of frontoinsular cortex, ventromedial prefrontal cortex, and lateral amygdala. Our  
403 primary analysis aimed to understand microstructure variation in frontoinsular cortex,  
404 due to the comprehensive literature showing its role in salience processing (Seeley et al.,  
405 2007; Uddin, 2015; Menon and Uddin, 2010), interoceptive awareness (Craig, 2009), pain,  
406 decision making (Wiech et al., 2010), among many others (Nieuwenhuys, 2012). There  
407 is a plausible relationship between known effects of cannabis and our insular findings,  
408 for example, the representation of flavor in insular cortex (integration of taste and ol-  
409 faction) (Small, 2010) and within the endocannabinoid system (Bellocchio et al., 2008);  
410 the processing of pain in anterior insula (Fazeli and Büchel, 2018; Wiech et al., 2010),  
411 and its commonality in gray matter morphometric studies of psychiatric illness (Good-  
412 kind et al., 2015). In addition to frontoinsular effects, the surface-based analysis showed  
413 the ventromedial prefrontal cortex as another discrete brain area where microstructure  
414 is related to THC exposure. Previous work has found that vmPFC serves a key role in  
415 emotional regulation (Hänsel and von Känel, 2008; Etkin et al., 2011), decision making  
416 (Bechara et al., 2000b; Fellows and Farah, 2007; Reber et al., 2017), and psychopathology  
417 (Hiser and Koenigs, 2018; Myers-Schulz and Koenigs, 2012). Beyond the cortical effects,  
418 our analysis also showed anatomically specific effects within lateral amygdala subfields.  
419 Previous work studying the amygdala has shown its importance in emotion recognition  
420 (Adolphs, 2002) and social judgement (Adolphs et al., 1998). In conjunction with fron-  
421 toinsular cortex, it is also involved in processing risk prediction error, uncertainty, and  
422 empathy (Singer et al., 2009; Decety and Michalska, 2010). Furthermore, Phan et al.  
423 (2008) showed related effects of THC on amygdala functional activity related to social  
424 signals, and our microstructure results show similar localization in lateral amygdala sub-

425 fields.

426 We can draw several parallels among the functional significance of these brain areas.  
427 It is plausible that the observed effects exist because these areas work in concert; indeed,  
428 tract tracing studies of non-humans have shown direct connections among these three  
429 areas (Mufson et al., 1981; Amaral and Price, 1984), and functional studies have shown  
430 direct regulation of amygdala function by ventromedial prefrontal cortex (Motzkin et al.,  
431 2015; Coombs III et al., 2014) and perfusion changes linked to negative affect (Coombs III  
432 et al., 2014). Lesion studies have also shown its role coordinating the vmPFC and insular  
433 cortex in risky decision making (Clark et al., 2008; Bechara et al., 2000b), and our effects  
434 may further be linked to past work showing a connection between paternal alcohol abuse,  
435 and subsequent risky decision making and substance abuse in offspring (Ohannessian and  
436 Hesselbrock, 2008). With regard to our AAIC and vmPFC findings, the work of Baldo  
437 et al. suggest these areas play causal role in regulating feeding behavior via a GABA  
438 agonist, which possibly relates to the analogous role of THC on GABA inhibition. The  
439 areas identified in our study have also been proposed as a possible anatomical substrate  
440 for the somatic marker hypothesis, whereby the amygdala, insular and vmPFC process  
441 emotions to subsequently guide decision making (Bechara et al., 2000a). A related point  
442 is that were also parietal brain areas which showed moderate but significant effects (and  
443 without bilaterality), including left hemisphere Brodmann areas 1, 7PL, and IP2, areas  
444 which all relate to somatosensory function. Furthermore, the meta-analysis by Goodkind  
445 et al. (2015) showed that while anterior insular cortex plays a role in both psychotic and  
446 non-psychotic psychiatric illnesses, the vmPFC exhibits specificity to psychotic cases,  
447 which is perhaps relevant to previously established associations between cannabis use  
448 and psychosis. In a direct comparison with their data, we found that our FIC and  
449 vmPFC regions have some overlap with those from the meta-analysis. In addition, given  
450 the pharmacological effects of THC on pain and the importance of frontoinsula cortex  
451 in the processing of pain expectation and prediction errors (Fazeli and Büchel, 2018;  
452 Craig, 2003; Hester et al., 2009), this supports the role of the endocannabinoid system  
453 in the processing of pain. Taking a broader view, our results suggest discrete brain areas  
454 in which the cannabinoid system may play its role in homeostatic regulation in which,  
455 as suggested by Volkow et al. (2017), it acts as a buffer against extreme experiences to  
456 promote well-being through its involvement in salience processing, emotion regulation,  
457 and decision making.

458 We can also drill further down to ask: what are plausible underlying cellular and  
459 molecular mechanisms that could produce these effects? One possibility is that our ob-  
460 servations reflect a change in microglia density or activation, as Yi et al. (2019) rigorously  
461 showed that ODI parametrically reflects microglia density. This possibility is supported  
462 by work directly showing changes in microglia in response to THC exposure (McHugh  
463 et al., 2014) and work showing that endocannabinoids are involved in microglia signaling

464 (Stella, 2009) and driving them from quiescent to activated states (Mecha et al., 2015).  
465 The coordination of microglia and endocannabinoids have further been suggested to be  
466 a component of psychiatric disorders (Lisboa et al., 2016; Mecha et al., 2016), which is  
467 supported by our findings related to negative intrusive thinking (Abdellaoui et al., 2012).  
468 However, because microglia are found throughout the brain, this does not adequately  
469 explain the anatomical specificity of our findings.

470 To account for this, we propose a more parsimonious molecular and cellular mech-  
471 anism: that THC exposure produces microstructural changes via the degradation of  
472 stathmin-2 (STMN2) at the presynaptic CB1 receptors (CBR1) of cholecystinin (CCK)  
473 basket cells. STMN2 is a protein involved in the structural maintenance and repair of axons  
474 in adults (Klim et al., 2019), and THC has been shown to cause STMN2 degradation in  
475 growing axons in fetal brains thus disrupting connectivity (Tortoriello et al., 2014). The  
476 proposed role of STMN2 is driven in part due to the anatomical distribution of our find-  
477 ings, which showed a notable absence of effects in some cannabinoid-receptor-rich nuclei,  
478 i.e. caudate and putamen. We consulted the Genotype-Tissue Expression (GTEx) Por-  
479 tal <sup>1</sup> and the Allen Brain Map Portal <sup>2</sup> to observe expression profiles of the cannabinoid  
480 receptor protein CNR1, which showed widespread expression across the brain, including  
481 all of the investigated brain areas; however the distribution STMN2 and CCK provide  
482 interesting constraints. In contrast to CNR1, STMN2 showed negligible expression in  
483 the caudate, putamen, and substantia nigra but substantial expression in the cortex and  
484 amygdala. Concerning the cellular component, CCK basket cells are common interneu-  
485 rons whose morphology and inhibitory action are influenced by cannabinoids (Trettel  
486 and Levine, 2003; Berghuis et al., 2007) potentially through the degradation of STMN2.  
487 They have been previously identified in prefrontal cortex (Eggan et al., 2010), amygdala  
488 (Rovira-Esteban et al., 2017), and hippocampus (Hartzell et al., 2018), and the GTEx  
489 and Allan maps of CCK indicate expression patterns analagous with our findings, that  
490 is, more in amygdala and cortex and much less in the hypothalamus, caudate, putamen,  
491 substantia nigra, and periaqueductal gray. While we did not observe microstructure ef-  
492 fects in hippocampus, we did observe significant differences in total hippocampal volume,  
493 similar to Owens et al. (2019), so higher resolution imaging data may be necessary to  
494 detect microstructural changes in the the thin layer that CCK cells occupy. Thus, the  
495 effects of THC on STMN2 in CCK basket cells provides a plausible candidate mechanism  
496 explaining microstructural changes that are observable with diffusion MRI and consistent  
497 with the brain areas identified in our analysis.

498 Finally, there are several relevant factors with greater specificity than may be mea-  
499 surable with MRI, yet are still worth discussing. For example, frontoinsular and area 24  
500 of ventromedial prefrontal cortex contain a unique and morphologically distinct popula-

---

<sup>1</sup><https://gtexportal.org/>

<sup>2</sup><https://portal.brain-map.org/>

tion of cells, known as von Economo Neurons (VENs) (Nimchinsky et al., 1999; Allman et al., 2010), and due to their large size and bipolar geometry (Watson et al., 2006), it is plausible that changes in the relative size or local density of VENs in FIC could be a relevant factor. Some previous work has shown that the diffusion signal reflects compartment sizes consistent with cell bodies and dendrites (Latour et al., 1994), and others have performed simulations suggesting the possibility of detecting VENs with multi-shell diffusion MRI (Menon et al., 2019). A final consideration is changes in dendritic spines and receptor density, which likely occur in conjunction with possible mechanisms described above. Specifically, there is evidence from Njoo et al. that cannabinoid receptor agonists cause the shrinkage of dendritic spines in mature cortical neurons in rodents, by selectively causing the collapse of the actin cytoskeleton within the spine (Njoo et al., 2015). Related work has shown similar changes in rodent dendritic spine morphology in prefrontal cortex (Miller et al., 2019), and when combined with stress, THC reduced mushroom spines in the rodent amygdala and impaired fear extinction (Saravia et al., 2019), which is perhaps relevant to acute THC side effects of anxiety and paranoia in humans. These possibilities align with the PET imaging finding that THC exposure downregulates CB1 receptor density (Hirvonen et al., 2012); however, it is unlikely these changes are directly observable with MRI, due to their fine spatial scale.

There are also several limitations which constrain what we can conclude from the present study. First and foremost, it is important to note that the causal nature of any explanation here should be carefully considered. While it could be that THC is causing changes in microstructure, it is also possible that distinct microstructure variants exist prior to THC exposure but predispose one to cannabis use through their behavioral correlates, e.g. impaired inhibition or a coping mechanism. However, our examination of self-reported cannabis use provides some cues related to dose-dependency, in which differences increased non-linearly with higher usage. However, it should be noted that the initial age of exposure is an important factor not explored in our study, and because endocannabinoids play a key role in neurodevelopment (Hurd et al., 2019), it would be valuable to understand how gray matter microstructure parameters vary in relation to adolescent exposure. The cross-sectional nature of the HCP young adult data prohibits a conclusive answer in this regard, requiring substantial further work that involves close tracking of THC exposure across the lifespan or perhaps with an interventional study design. Furthermore, while we examined THC exposure here through a specific urine screen, participants may have been co-exposed to other phytocannabinoids, depending on the method of self-administration.

Regarding neuroimaging, our image analysis examined diffusion MRI estimates of microstructure properties, an approach that is powerful but with notable challenges related to data interpretation. MRI parameters are essentially statistical summaries of what is a large section of tissue, relative to the physical scale of neurons and other cells. Diffusion

540 modeling has been shown in previous evaluation work to be sensitive to a variety of neu-  
541 ronol scale tissue properties, such as fiber coherence, packing density, myelination, etc.  
542 (Beaulieu, 2002); however, there remain challenges regarding its specificity in isolating  
543 the effects of any one of these factors. We employed two diffusion modeling approaches  
544 in an attempt to depict more specific organizational properties: first, we found effects  
545 related to FA using DTI; second, we complemented this with NODDI, an approach that  
546 shows promise in isolating the effects of neurite dispersion (Mollink et al., 2017; Schilling  
547 et al., 2018). These parameters show an interesting connection in gray matter; similar  
548 to Fukutomi et al. (2018), we found a high negative correlation between FA and ODI  
549 (Pearson’s  $r = -0.78$ ). Furthermore, our experiments showed that NODDI ODI afforded  
550 greater sensitivity than DTI FA, suggesting that the findings may be distinguishable from  
551 neurite density, myelination, etc. In nearly all cases, the effect size of ODI was greater  
552 than tensor anisotropy, suggesting that NODDI may provide distinct anatomical infor-  
553 mation for mapping the effects of THC exposure in gray matter. Finally, subsequent  
554 work could explore cerebellar gray matter, as it strongly expresses CNR1; however, there  
555 are challenges associated with surface-based modeling of cerebellar cortex and the op-  
556 timization of NODDI fixed parameters in this region that require further attention as  
557 well.

558 In conclusion, the present study demonstrated strong associations between THC expo-  
559 sure and the differential organization of microstructure in the cerebral cortex and amyg-  
560 dala in a large cohort of young adults. We identified frontoinsula cortex, ventromedial  
561 prefrontal cortex, and the lateral amygdala as brain areas with the greatest relative differ-  
562 ences in microstructure and found connections of these brain areas to independent effects  
563 in behavioral measures of memory, negative intrusive thinking, and paternal substance  
564 abuse. Given the increased usage of cannabis in many parts of the world, it is impor-  
565 tant to have a more complete understanding of how THC affects the brain. Our study  
566 complements a rich literature of neuroimaging studies of THC usage, and we expand on  
567 these past findings by showing that brain areas for salience processing, emotion regula-  
568 tion, and decision making also exhibit microstructure differences. Such structural effects  
569 potentially raise concerns regarding the long term effects of cannabis use, and further  
570 studies are warranted to characterize the longitudinal nature of the onset and persistence  
571 of these effects across the lifespan and to investigate the causal neurobiological factors  
572 connecting THC exposure to microstructure changes in the endocannabinoid system.

## 573 **Acknowledgements**

574 This work was supported by National Institutes of Health (grant number P41EB015922).

575

576 Corresponding author:

577 Ryan P. Cabeen, PhD  
578 2025 Zonal Ave, Los Angeles, CA 90033  
579 Email: rcabeen@loni.usc.edu  
580 Telephone: 323-865-1767  
581 Fax: 323-442-0137

## 582 **References**

- 583 A. Abdellaoui, M. H. de Moor, L. M. Geels, J. H. Van Beek, G. Willemsen, and D. I.  
584 Boomsma. Thought problems from adolescence to adulthood: Measurement invariance  
585 and longitudinal heritability. *Behavior Genetics*, 42(1):19–29, 2012.
- 586 T. M. Achenbach and L. Rescorla. Manual for the ASEBA adult forms & profiles, 2003.
- 587 R. Adolphs. Neural systems for recognizing emotion. *Current Opinion in Neurobiology*,  
588 12(2):169–177, 2002.
- 589 R. Adolphs, D. Tranel, and A. R. Damasio. The human amygdala in social judgment.  
590 *Nature*, 393(6684):470, 1998.
- 591 A. Agrawal, P. A. Madden, K. K. Bucholz, A. C. Heath, and M. T. Lynskey. Initial  
592 reactions to tobacco and cannabis smoking: a twin study. *Addiction*, 109(4):663–671,  
593 2014.
- 594 J. M. Allman, N. A. Tetreault, A. Y. Hakeem, K. F. Manaye, K. Semendeferi, J. M.  
595 Erwin, S. Park, V. Goubert, and P. R. Hof. The von Economo neurons in frontoinsular  
596 and anterior cingulate cortex in great apes and humans. *Brain Structure and Function*,  
597 214(5-6):495–517, 2010.
- 598 D. G. Amaral and J. Price. Amygdalo-cortical projections in the monkey (*Macaca fasci-*  
599 *cularis*). *Journal of Comparative Neurology*, 230(4):465–496, 1984.
- 600 C. Andrade. Cannabis and neuropsychiatry, 2: The longitudinal risk of psychosis as an  
601 adverse outcome. *The Journal of Clinical Psychiatry*, 77(6):e739–42, 2016.
- 602 C. M. Andre, J. Hausman, and G. Guerriero. Cannabis sativa: The plant of the thousand  
603 and one molecules. *Front Plant Sci*, 7:19, 2016. doi: 10.3389/fpls.2016.00019.
- 604 M. H. Andrae, G. M. Carter, N. Shaparin, K. Suslov, R. J. Ellis, M. A. Ware, D. I.  
605 Abrams, H. Prasad, B. Wilsey, D. Indyk, et al. Inhaled cannabis for chronic neuropathic  
606 pain: a meta-analysis of individual patient data. *The Journal of Pain*, 16(12):1221–  
607 1232, 2015.

- 608 D. Arnone, T. Barrick, S. Chengappa, C. Mackay, C. Clark, and A. M.T. Corpus callosum  
609 damage in heavy marijuana use: Preliminary evidence from diffusion tensor tractog-  
610 raphy and tract-based spatial statistics. *NeuroImage*, 41(3):1067–1074, 2008. ISSN  
611 1053-8119. doi: 10.1016/j.neuroimage.2008.02.064.
- 612 M. Ashtari, K. Cervellione, J. Cottone, B. A. Ardekani, S. Sevy, and S. Kumra. Diffusion  
613 abnormalities in adolescents and young adults with a history of heavy cannabis use. *J*  
614 *Psychiatr Res*, 43(3):189–204, 2009. ISSN 0022-3956. doi: 10.1016/j.jpsychires.2008.  
615 12.002.
- 616 B. B. Avants, C. L. Epstein, M. Grossman, and J. C. Gee. Symmetric diffeomorphic  
617 image registration with cross-correlation: evaluating automated labeling of elderly and  
618 neurodegenerative brain. *Medical Image Analysis*, 12(1):26–41, 2008.
- 619 P. J. Basser and D. K. Jones. Diffusion-tensor MRI: theory, experimental design and data  
620 analysis—a technical review. *NMR in Biomedicine: An International Journal Devoted*  
621 *to the Development and Application of Magnetic Resonance In Vivo*, 15(7-8):456–467,  
622 2002.
- 623 A. Batalla, S. Bhattacharyya, M. Yuecel, P. Fusar-Poli, J. A. Crippa, S. Nogue, M. Tor-  
624 rens, J. Pujol, M. Farre, and R. Martin-Santos. Structural and functional imaging  
625 studies in chronic cannabis users: a systematic review of adolescent and adult findings.  
626 *PloS one*, 8(2):e55821, 2013a.
- 627 A. Batalla, S. Bhattacharyya, M. Yuecel, P. Fusar-Poli, J. A. Crippa, S. Nogue, M. Tor-  
628 rens, J. Pujol, M. Farre, and R. Martin-Santos. Structural and functional imaging  
629 studies in chronic cannabis users: a systematic review of adolescent and adult findings.  
630 *PloS one*, 8(2):e55821, 2013b.
- 631 G. Battistella, E. Fornari, A. Thomas, J.-F. Mall, H. Chtioui, M. Appenzeller, J.-M.  
632 Annoni, B. Favrat, P. Maeder, and C. Giroud. Weed or wheel! FMRI, behavioural,  
633 and toxicological investigations of how cannabis smoking affects skills necessary for  
634 driving. *PloS one*, 8(1):e52545, 2013.
- 635 G. Battistella, E. Fornari, J.-M. Annoni, H. Chtioui, K. Dao, M. Fabritius, B. Favrat,  
636 J.-F. Mall, P. Maeder, and C. Giroud. Long-term effects of cannabis on brain structure.  
637 *Neuropsychopharmacology*, 39(9):2041, 2014.
- 638 C. Beaulieu. The basis of anisotropic water diffusion in the nervous system—a technical  
639 review. *NMR in Biomedicine: An International Journal Devoted to the Development*  
640 *and Application of Magnetic Resonance In Vivo*, 15(7-8):435–455, 2002.
- 641 A. Bechara, H. Damasio, and A. R. Damasio. Emotion, decision making and the or-  
642 bitofrontal cortex. *Cerebral Cortex*, 10(3):295–307, 2000a.

- 643 A. Bechara, D. Tranel, and H. Damasio. Characterization of the decision-making deficit of  
644 patients with ventromedial prefrontal cortex lesions. *Brain*, 123(11):2189–2202, 2000b.
- 645 M. P. Becker, P. F. Collins, K. O. Lim, R. Muetzel, and M. Luciana. Longitudinal changes  
646 in white matter microstructure after heavy cannabis use. *Dev Cogn Neuros-neth*, 16:  
647 23–35, 2015. ISSN 1878-9293. doi: 10.1016/j.dcn.2015.10.004.
- 648 L. Bellocchio, C. Cervino, R. Pasquali, and U. Pagotto. The endocannabinoid system  
649 and energy metabolism. *Journal of Neuroendocrinology*, 20(6):850–857, 2008.
- 650 Y. Benjamini and Y. Hochberg. Controlling the false discovery rate: a practical and  
651 powerful approach to multiple testing. *Journal of the Royal statistical society: series*  
652 *B (Methodological)*, 57(1):289–300, 1995.
- 653 P. Berghuis, A. M. Rajnicek, Y. M. Morozov, R. A. Ross, J. Mulder, G. M. Urbán,  
654 K. Monory, G. Marsicano, M. Matteoli, A. Canty, et al. Hardwiring the brain: endo-  
655 cannabinoids shape neuronal connectivity. *Science*, 316(5828):1212–1216, 2007.
- 656 S. Bhattacharyya, J. A. Crippa, P. Allen, R. Martin-Santos, S. Borgwardt, P. Fusar-Poli,  
657 K. Rubia, J. Kambeitz, C. OCarroll, M. L. Seal, et al. Induction of psychosis by  $\delta$ 9-  
658 tetrahydrocannabinol reflects modulation of prefrontal and striatal function during  
659 attentional salience processing. *Archives of general psychiatry*, 69(1):27–36, 2012.
- 660 S. Bhattacharyya, I. Falkenberg, R. Martin-Santos, Z. Atakan, J. A. Crippa, V. Giampietro,  
661 M. Brammer, and P. McGuire. Cannabinoid modulation of functional connectivity  
662 within regions processing attentional salience. *Neuropsychopharmacology*, 40(6):1343,  
663 2015.
- 664 M. A. Bloomfield, C. Hindocha, S. F. Green, M. B. Wall, R. Lees, K. Petrilli, H. Costello,  
665 M. O. Ogunbiyi, M. G. Bossong, and T. P. Freeman. The neuropsychopharmacology  
666 of cannabis: a review of human imaging studies. *Pharmacology & therapeutics*, 2018.
- 667 S. Borgwardt, P. Allen, S. Bhattacharyya, F. P. J. Crippa, M. Seal, V. Fraccaro,  
668 Z. Atakan, M. R. O. C, K. Rubia, and M. P.K. S39-03 neurofunctional effects of  
669 cannabis on response inhibition. *Eur Psychiat*, 24:S208, 2009. ISSN 0924-9338. doi:  
670 10.1016/s0924-9338(09)70441-9.
- 671 S. J. Broyd, H. H. van Hell, C. Beale, M. Yucel, and N. Solowij. Acute and chronic  
672 effects of cannabinoids on human cognition—a systematic review. *Biological psychiatry*,  
673 79(7):557–567, 2016.
- 674 R. Cabeen, D. Laidlaw, and A. Toga. Quantitative Imaging Toolkit: Software for Interac-  
675 tive 3D Visualization, Data Exploration, and Computational Analysis of Neuroimaging

- 676 Datasets. In *Proc International Society for Magnetic Resonance in Medicine (ISMRM)*,  
677 volume 2018:2854, 2018.
- 678 R. Cabeen, F. Sepehrband, and A. Toga. Rapid and Accurate NODDI Parameter Esti-  
679 mation with the Spherical Mean Technique. In *Proc International Society for Magnetic*  
680 *Resonance in Medicine (ISMRM)*, volume 2019:3363, 2019.
- 681 J. C. Churchwell, M. Lopez-Larson, and D. A. Yurgelun-Todd. Altered frontal cortical  
682 volume and decision making in adolescent cannabis users. *Frontiers in Psychology*, 1:  
683 225, 2010.
- 684 L. Clark, A. Bechara, H. Damasio, M. Aitken, B. Sahakian, and T. Robbins. Differential  
685 effects of insular and ventromedial prefrontal cortex lesions on risky decision-making.  
686 *Brain*, 131(5):1311–1322, 2008.
- 687 M. Colizzi, P. McGuire, V. Giampietro, S. Williams, M. Brammer, and S. Bhat-  
688 tacharyya. Previous cannabis exposure modulates the acute effects of delta-9-  
689 tetrahydrocannabinol on attentional salience and fear processing. *Experimental and*  
690 *clinical psychopharmacology*, 26(6):582, 2018.
- 691 G. Coombs III, M. L. Loggia, D. N. Greve, and D. J. Holt. Amygdala perfusion is  
692 predicted by its functional connectivity with the ventromedial prefrontal cortex and  
693 negative affect. *PloS one*, 9(5):e97466, 2014.
- 694 A. Craig. A new view of pain as a homeostatic emotion. *Trends in Neurosciences*, 26(6):  
695 303–307, 2003.
- 696 A. Craig. How do you feel–now? the anterior insula and human awareness. *Nature*  
697 *Reviews Neuroscience*, 10(1), 2009.
- 698 J. Decety and K. J. Michalska. Neurodevelopmental changes in the circuits underlying  
699 empathy and sympathy from childhood to adulthood. *Developmental science*, 13(6):  
700 886–899, 2010.
- 701 W. A. Devane, F. r. Dysarz, M. R. Johnson, L. S. Melvin, and A. C. Howlett. De-  
702 termination and characterization of a cannabinoid receptor in rat brain. *Molecular*  
703 *Pharmacology*, 34(5):605–613, 1988.
- 704 W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson,  
705 A. Mandelbaum, A. Etinger, and R. Mechoulam. Isolation and structure of a brain  
706 constituent that binds to the cannabinoid receptor. *Science*, 258(5090):1946–1949,  
707 1992.

- 708 I. Dinov, J. Van Horn, K. Lozev, R. Magsipoc, P. Petrosyan, Z. Liu, A. MacKenzie-  
709 Graha, P. Eggert, D. S. Parker, and A. W. Toga. Efficient, distributed and interactive  
710 neuroimaging data analysis using the loni pipeline. *Frontiers in Neuroinformatics*, 3:  
711 22, 2009.
- 712 S. M. Eggan, D. S. Melchitzky, S. R. Sesack, K. N. Fish, and D. A. Lewis. Relationship of  
713 cannabinoid cb1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral  
714 prefrontal cortex. *Neuroscience*, 169(4):1651–1661, 2010.
- 715 M. A. ElSohly, W. Gul, A. S. Wanas, and M. M. Radwan. Synthetic cannabinoids:  
716 analysis and metabolites. *Life sciences*, 97(1):78–90, 2014.
- 717 A. Etkin, T. Egner, and R. Kalisch. Emotional processing in anterior cingulate and  
718 medial prefrontal cortex. *Trends in cognitive sciences*, 15(2):85–93, 2011.
- 719 S. Fazeli and C. Büchel. Pain-related expectation and prediction error signals in the  
720 anterior insula are not related to aversiveness. *Journal of Neuroscience*, 38(29):6461–  
721 6474, 2018.
- 722 L. K. Fellows and M. J. Farah. The role of ventromedial prefrontal cortex in decision  
723 making: judgment under uncertainty or judgment per se? *Cerebral Cortex*, 17(11):  
724 2669–2674, 2007.
- 725 B. Fischl. Freesurfer. *NeuroImage*, 62(2):774–781, 2012.
- 726 T. F. Freund, I. Katona, and D. Piomelli. Role of endogenous cannabinoids in synaptic  
727 signaling. *Physiological reviews*, 83(3):1017–1066, 2003.
- 728 H. Fukutomi, M. F. Glasser, H. Zhang, J. A. Autio, T. S. Coalson, T. Okada, K. Togashi,  
729 D. C. Van Essen, and T. Hayashi. Neurite imaging reveals microstructural variations  
730 in human cerebral cortical gray matter. *NeuroImage*, 182:488–499, 2018.
- 731 J. M. Gilman, J. K. Kuster, S. Lee, M. Lee, B. Kim, N. Makris, A. van der Kouwe,  
732 A. J. Blood, and H. C. Breiter. Cannabis use is quantitatively associated with nucleus  
733 accumbens and amygdala abnormalities in young adult recreational users. *J Neurosci*,  
734 34(16):5529–5538, 2014. ISSN 0270-6474. doi: 10.1523/jneurosci.4745-13.2014.
- 735 M. Glass, R. Faull, and M. Dragunow. Cannabinoid receptors in the human brain: a  
736 detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and  
737 adult human brain. *Neuroscience*, 77(2):299–318, 1997.
- 738 M. F. Glasser, S. N. Sotiropoulos, J. A. Wilson, T. S. Coalson, B. Fischl, J. L. Andersson,  
739 J. Xu, S. Jbabdi, M. Webster, J. R. Polimeni, et al. The minimal preprocessing pipelines  
740 for the human connectome project. *NeuroImage*, 80:105–124, 2013.

- 741 M. F. Glasser, T. S. Coalson, E. C. Robinson, C. D. Hacker, J. Harwell, E. Yacoub,  
742 K. Ugurbil, J. Andersson, C. F. Beckmann, M. Jenkinson, et al. A multi-modal par-  
743 cellation of human cerebral cortex. *Nature*, 536(7615):171, 2016.
- 744 R. Gonzalez. Acute and non-acute effects of cannabis on brain functioning and neuropsy-  
745 chological performance. *Neuropsychology review*, 17(3):347–361, 2007.
- 746 M. Goodkind, S. B. Eickhoff, D. J. Oathes, Y. Jiang, A. Chang, L. B. Jones-Hagata, B. N.  
747 Ortega, Y. V. Zaiko, E. L. Roach, M. S. Korgaonkar, et al. Identification of a common  
748 neurobiological substrate for mental illness. *JAMA Psychiatry*, 72(4):305–315, 2015.
- 749 B. Green, D. Kavanagh, and R. Young. Being stoned: a review of self-reported cannabis  
750 effects. *Drug and alcohol review*, 22(4):453–460, 2003.
- 751 F. Grotenhermen. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clinical*  
752 *pharmacokinetics*, 42(4):327–360, 2003.
- 753 F. Grotenhermen and K. Müller-Vahl. The therapeutic potential of cannabis and cannabi-  
754 noids. *Deutsches Ärzteblatt International*, 109(29-30):495, 2012.
- 755 S. A. Gruber, M. M. Silveri, M. Dahlgren, and Y. Deborah. Why so impulsive? white  
756 matter alterations are associated with impulsivity in chronic marijuana smokers. *Exp*  
757 *Clin Psychopharm*, 19(3):231, 2011. ISSN 1064-1297. doi: 10.1037/a0023034.
- 758 W. Hall. What has research over the past two decades revealed about the adverse health  
759 effects of recreational cannabis use? *Addiction*, 110(1):19–35, 2015. ISSN 1360-0443.  
760 doi: 10.1111/add.12703.
- 761 W. Hall and L. Degenhardt. Adverse health effects of non-medical cannabis use. *Lancet*,  
762 374(9698):1383–1391, 2009. ISSN 0140-6736. doi: 10.1016/s0140-6736(09)61037-0.
- 763 M. Haney and M. N. Hill. Cannabis and cannabinoids: From synapse to society. *Neu-*  
764 *ropsychopharmacol*, 43(1):1, 2018. ISSN 1740-634X. doi: 10.1038/npp.2017.255.
- 765 A. Hänsel and R. von Känel. The ventro-medial prefrontal cortex: a major link between  
766 the autonomic nervous system, regulation of emotion, and stress reactivity? *BioPsy-*  
767 *choSocial Medicine*, 2(1):21, 2008.
- 768 I. H. Harding, N. Solowij, B. J. Harrison, M. Takagi, V. Lorenzetti, D. I. Lubman, M. L.  
769 Seal, C. Pantelis, and M. Yücel. Functional connectivity in brain networks underlying  
770 cognitive control in chronic cannabis users. *Neuropsychopharmacology*, 37(8):1923,  
771 2012.

- 772 A. L. Hartzell, K. M. Martyniuk, G. S. Brigidi, D. A. Heinz, N. A. Djaja, A. Payne, and  
773 B. L. Bloodgood. Npas4 recruits cck basket cell synapses and enhances cannabinoid-  
774 sensitive inhibition in the mouse hippocampus. *Elife*, 7:e35927, 2018.
- 775 D. S. Hasin. US epidemiology of cannabis use and associated problems. *Neuropsychophar-*  
776 *macol*, 43(1):195, 2017. ISSN 1740-634X. doi: 10.1038/npp.2017.198.
- 777 M. M. Heitzeg, L. M. Cope, M. E. Martz, J. E. Hardee, and R. A. Zucker. Brain activation  
778 to negative stimuli mediates a relationship between adolescent marijuana use and later  
779 emotional functioning. *Dev Cogn Neuros-neth*, 16:71–83, 2015. ISSN 1878-9293. doi:  
780 10.1016/j.dcn.2015.09.003.
- 781 M. Herkenham, A. B. Lynn, M. D. Little, M. R. Johnson, L. S. Melvin, B. R. De Costa,  
782 and K. C. Rice. Cannabinoid receptor localization in brain. *Proceedings of the national*  
783 *Academy of sciences*, 87(5):1932–1936, 1990.
- 784 R. Hester, L. Nestor, and H. Garavan. Impaired error awareness and anterior cingulate  
785 cortex hypoactivity in chronic cannabis users. *Neuropsychopharmacology*, 34(11):2450,  
786 2009.
- 787 J. Hirvonen, R. Goodwin, C.-T. Li, G. Terry, S. Zoghbi, C. Morse, V. Pike, N. Volkow,  
788 M. Huestis, and R. Innis. Reversible and regionally selective downregulation of brain  
789 cannabinoid cb 1 receptors in chronic daily cannabis smokers. *Molecular psychiatry*,  
790 17(6):642, 2012.
- 791 J. Hiser and M. Koenigs. The multifaceted role of the ventromedial prefrontal cortex in  
792 emotion, decision making, social cognition, and psychopathology. *Biological Psychiatry*,  
793 83(8):638–647, 2018.
- 794 M. Hlavac. stargazer: Latex code and ascii text for well-formatted regression and sum-  
795 mary statistics tables. URL: <http://CRAN.R-project.org/package=stargazer>, 2013.
- 796 A. R. Hoy, C. G. Koay, S. R. Kecskesteti, and A. L. Alexander. Optimization of a free  
797 water elimination two-compartment model for diffusion tensor imaging. *NeuroImage*,  
798 103:323–333, 2014.
- 799 T. Hua, K. Vemuri, M. Pu, L. Qu, G. W. Han, Y. Wu, S. Zhao, W. Shui, S. Li, A. Korde,  
800 et al. Crystal structure of the human cannabinoid receptor cb1. *Cell*, 167(3):750–762,  
801 2016.
- 802 Y. L. Hurd, O. J. Manzoni, M. V. Pletnikov, F. S. Lee, S. Bhattacharyya, and M. Melis.  
803 Cannabis and the developing brain: Insights into its long-lasting effects. *Journal of*  
804 *Neuroscience*, 39(42):8250–8258, 2019.

- 805 J. Jacobus, L. Squeglia, M. Infante, S. Bava, and T. S. sciences. White matter integrity  
806 pre-and post marijuana and alcohol initiation in adolescence. *Brain sciences*, 2013.  
807 doi: 10.3390/brainsci3010396.
- 808 J. Jacobus, L. M. Squeglia, A. D. Meruelo, N. Castro, T. Brumback, J. N. Giedd, and  
809 S. F. Tapert. Cortical thickness in adolescent marijuana and alcohol users: A three-  
810 year prospective study from adolescence to young adulthood. *Dev Cogn Neuros-neth*,  
811 16:101–109, 2015. ISSN 1878-9293. doi: 10.1016/j.dcn.2015.04.006.
- 812 M. Jenkinson, C. F. Beckmann, T. E. Behrens, M. W. Woolrich, and S. M. Smith. FSL.  
813 *NeuroImage*, 62(2):782–790, 2012.
- 814 R. E. Kass and A. E. Raftery. Bayes factors. *Journal of the American Statistical Asso-*  
815 *ciation*, 90(430):773–795, 1995.
- 816 J. R. Klim, L. A. Williams, F. Limone, I. G. San Juan, B. N. Davis-Dusenbery, D. A.  
817 Mordes, A. Burberry, M. J. Steinbaugh, K. K. Gamage, R. Kirchner, et al. Al-  
818 implicated protein tdp-43 sustains levels of stmn2, a mediator of motor neuron growth  
819 and repair. *Nature neuroscience*, 22(2):167–179, 2019.
- 820 A. C. Kreitzer and W. G. Regehr. Retrograde signaling by endocannabinoids. *Current*  
821 *Opinion in Neurobiology*, 12(3):324–330, 2002.
- 822 M. Large, S. Sharma, M. T. Compton, T. Slade, and O. Nielssen. Cannabis use and  
823 earlier onset of psychosis: a systematic meta-analysis. *Archives of general psychiatry*,  
824 68(6):555–561, 2011.
- 825 L. L. Latour, K. Svoboda, P. P. Mitra, and C. H. Sotak. Time-dependent diffusion of  
826 water in a biological model system. *Proceedings of the National Academy of Sciences*,  
827 91(4):1229–1233, 1994.
- 828 S. F. Lisboa, F. V. Gomes, F. S. Guimaraes, and A. C. Campos. Microglial cells as a link  
829 between cannabinoids and the immune hypothesis of psychiatric disorders. *Frontiers*  
830 *in Neurology*, 7:5, 2016.
- 831 K. M. Lisdahl, N. E. Wright, M. Christopher, K. E. Maple, and S. Shollenbarger. Con-  
832 sidering cannabis: The effects of regular cannabis use on neurocognition in adolescents  
833 and young adults. *Curr Addict Reports*, 1(2):144–156, 2014. doi: 10.1007/s40429-014-  
834 0019-6.
- 835 T. Long, M. Wagner, D. Demske, C. Leipe, and P. E. Tarasov. Cannabis in eurasia:  
836 origin of human use and bronze age trans-continental connections. *Vegetation History*  
837 *and Archaeobotany*, 26(2):245–258, 2017.

- 838 M. P. Lopez-Larson, P. Bogorodzki, J. Rogowska, E. McGlade, J. B. King, J. Terry,  
839 and D. Yurgelun-Todd. Altered prefrontal and insular cortical thickness in adolescent  
840 marijuana users. *Behavioural brain research*, 220(1):164–172, 2011.
- 841 V. Lorenzetti, Y. Chye, P. Silva, N. Solowij, and C. A. Roberts. Does regular cannabis use  
842 affect neuroanatomy? an updated systematic review and meta-analysis of structural  
843 neuroimaging studies. *European Archives of Psychiatry and Clinical Neuroscience*, 269  
844 (1):59–71, 2019.
- 845 K. Mackie and N. Stella. Cannabinoid receptors and endocannabinoids: evidence for new  
846 players. *The AAPS journal*, 8(2):E298–E306, 2006.
- 847 P. Manza, E. Shokri-Kojori, and N. D. Volkow. Reduced segregation between cognitive  
848 and emotional processes in cannabis dependence. *Cerebral Cortex*, 2019.
- 849 A. Marconi, M. Di Forti, C. M. Lewis, R. M. Murray, and E. Vassos. Meta-analysis of  
850 the association between the level of cannabis use and risk of psychosis. *Schizophrenia  
851 bulletin*, 42(5):1262–1269, 2016.
- 852 R. J. Mathew, W. H. Wilson, R. E. Coleman, T. G. Turkington, and T. R. DeGrado.  
853 Marijuana intoxication and brain activation in marijuana smokers. *Life sciences*, 60  
854 (23):2075–2089, 1997.
- 855 R. D. Mattes, K. Engelman, L. M. Shaw, and M. A. Elsohly. Cannabinoids and appetite  
856 stimulation. *Pharmacol Biochem Be*, 49(1):187–195, 1994. ISSN 0091-3057. doi: 10.  
857 1016/0091-3057(94)90475-8.
- 858 D. McHugh, D. Roskowski, S. Xie, and H. B. Bradshaw.  $\delta$ 9-thc and n-arachidonoyl glycine  
859 regulate bv-2 microglial morphology and cytokine release plasticity: implications for  
860 signaling at gpr18. *Frontiers in Pharmacology*, 4:162, 2014.
- 861 M. Mecha, A. Feliú, F. Carrillo-Salinas, A. Rueda-Zubiaurre, S. Ortega-Gutiérrez, R. G.  
862 de Sola, and C. Guaza. Endocannabinoids drive the acquisition of an alternative phe-  
863 notype in microglia. *Brain, Behavior, and Immunity*, 49:233–245, 2015.
- 864 M. Mecha, F. Carrillo-Salinas, A. Feliú, L. Mestre, and C. Guaza. Microglia activation  
865 states and cannabinoid system: Therapeutic implications. *Pharmacology & Therapeu-  
866 tics*, 166:40–55, 2016.
- 867 K. Medina, B. Nagel, and T. S. Neuroimaging. Abnormal cerebellar morphometry in  
868 abstinent adolescent marijuana users. *Psychiatry Research: Neuroimaging*, 2010.
- 869 V. Menon and L. Q. Uddin. Saliency, switching, attention and control: a network model  
870 of insula function. *Brain Structure and Function*, 214(5-6):655–667, 2010.

- 871 V. Menon, G. Guillermo, M. A. Pinsk, V.-D. Nguyen, J.-R. Li, W. Cai, and D. Wasser-  
872 mann. Quantitative modeling links in vivo microstructural and macrofunctional orga-  
873 nization of human and macaque insular cortex, and predicts cognitive control abilities.  
874 *bioRxiv*, page 662601, 2019.
- 875 M. L. Miller, B. Chadwick, D. L. Dickstein, I. Purushothaman, G. Egervari, T. Rahman,  
876 C. Tessereau, P. R. Hof, P. Roussos, L. Shen, et al. Adolescent exposure to  $\delta$  9-  
877 tetrahydrocannabinol alters the transcriptional trajectory and dendritic architecture  
878 of prefrontal pyramidal neurons. *Molecular Psychiatry*, 24(4):588, 2019.
- 879 K. E. Moeller, J. C. Kissack, R. S. Atayee, and K. C. Lee. Clinical interpretation of urine  
880 drug tests: what clinicians need to know about urine drug screens. In *Mayo Clinic*  
881 *Proceedings*, volume 92, pages 774–796. Elsevier, 2017.
- 882 J. Mollink, M. Kleinnijenhuis, A.-M. v. C. van Walsum, S. N. Sotiropoulos, M. Cottaar,  
883 C. Mirfin, M. P. Heinrich, M. Jenkinson, M. Pallegage-Gamarallage, O. Ansorge, et al.  
884 Evaluating fibre orientation dispersion in white matter: comparison of diffusion mri,  
885 histology and polarized light imaging. *NeuroImage*, 157:561–574, 2017.
- 886 T. H. Moore, S. Zammit, L. Anne, T. R. Barnes, P. B. Jones, M. Burke, and G. Lewis.  
887 Cannabis use and risk of psychotic or affective mental health outcomes: a systematic  
888 review. *Lancet*, 370(9584):319–328, 2007. ISSN 0140-6736. doi: 10.1016/s0140-6736(07)  
889 61162-3.
- 890 J. C. Motzkin, C. L. Philippi, R. C. Wolf, M. K. Baskaya, and M. Koenigs. Ventromedial  
891 prefrontal cortex is critical for the regulation of amygdala activity in humans. *Biological*  
892 *Psychiatry*, 77(3):276–284, 2015.
- 893 E. Mufson, M.-M. Mesulam, and D. Pandya. Insular interconnections with the amygdala  
894 in the rhesus monkey. *Neuroscience*, 6(7):1231–1248, 1981.
- 895 R. M. Murray, P. D. Morrison, C. Henquet, and M. Forti. Cannabis, the mind and  
896 society: the hash realities. *Nat Rev Neurosci*, 8(11):nrn2253, 2007. ISSN 1471-0048.  
897 doi: 10.1038/nrn2253.
- 898 B. Myers-Schulz and M. Koenigs. Functional anatomy of ventromedial prefrontal cortex:  
899 implications for mood and anxiety disorders. *Molecular Psychiatry*, 17(2):132, 2012.
- 900 National Academies of Sciences, Engineering, and Medicine and others. *The health effects*  
901 *of cannabis and cannabinoids: The current state of evidence and recommendations for*  
902 *research*. National Academies Press, 2017.
- 903 L. Nestor, R. Hester, and H. Garavan. Increased ventral striatal bold activity during  
904 non-drug reward anticipation in cannabis users. *Neuroimage*, 49(1):1133–1143, 2010.

- 905 R. Nieuwenhuys. The insular cortex: a review. In *Progress in Brain Research*, volume  
906 195, pages 123–163. Elsevier, 2012.
- 907 E. A. Nimchinsky, E. Gilissen, J. M. Allman, D. P. Perl, J. M. Erwin, and P. R. Hof.  
908 A neuronal morphologic type unique to humans and great apes. *Proceedings of the*  
909 *National Academy of Sciences*, 96(9):5268–5273, 1999.
- 910 C. Njoo, N. Agarwal, B. Lutz, and R. Kuner. The cannabinoid receptor cb1 interacts  
911 with the wave1 complex and plays a role in actin dynamics and structural plasticity in  
912 neurons. *PLoS Biology*, 13(10):e1002286, 2015.
- 913 C. M. Ohannessian and V. M. Hesselbrock. Paternal alcoholism and youth substance  
914 abuse: the indirect effects of negative affect, conduct problems, and risk taking. *Journal*  
915 *of Adolescent Health*, 42(2):198–200, 2008.
- 916 J. M. Orr, C. J. Paschall, and M. T. Banich. Recreational marijuana use impacts white  
917 matter integrity and subcortical (but not cortical) morphometry. *NeuroImage: Clinical*,  
918 12:47–56, 2016.
- 919 M. M. Owens, J. MacKillop, and L. H. Sweet. Cannabis use is associated with lower hip-  
920 pocampus and amygdala volume: High-resolution segmentation of structural subfields  
921 in a large non-clinical sample. *PsyArXiv*, <https://doi.org/10.31234/osf.io/3xytq>, 2019.
- 922 D. Pagliaccio, D. M. Barch, R. Bogdan, P. K. Wood, M. T. Lynskey, A. C. Heath,  
923 and A. Agrawal. Shared predisposition in the association between cannabis use and  
924 subcortical brain structure. *JAMA Psychiatry*, 72(10):994–1001, 2015.
- 925 W. M. Pauli, A. N. Nili, and J. M. Tyszka. A high-resolution probabilistic in vivo atlas  
926 of human subcortical brain nuclei. *Scientific data*, 5:180063, 2018.
- 927 T. Petker, M. M. Owens, M. T. Amlung, A. Oshri, L. H. Sweet, and J. MacKillop.  
928 Cannabis involvement and neuropsychological performance: findings from the human  
929 connectome project. *Journal of Psychiatry Neuroscience*, 44(5):1–9, 2019.
- 930 K. L. Phan, M. Angstadt, J. Golden, I. Onyewuenyi, A. Popovska, and H. de Wit.  
931 Cannabinoid modulation of amygdala reactivity to social signals of threat in humans.  
932 *Journal of neuroscience*, 28(10):2313–2319, 2008.
- 933 J. Quickfall and D. Crockford. Brain neuroimaging in cannabis use: A review. *J Neu-*  
934 *ropsychiatry Clin Neurosci*, 18(3):318–332, 2006. ISSN 0895-0172. doi: 10.1176/jnp.  
935 2006.18.3.318.
- 936 J. Reber, J. S. Feinstein, J. P. O’Doherty, M. Liljeholm, R. Adolphs, and D. Tranel.  
937 Selective impairment of goal-directed decision-making following lesions to the human  
938 ventromedial prefrontal cortex. *Brain*, 140(6):1743–1756, 2017.

- 939 S. Rigucci, T. Marques, D. M. Forti, H. Taylor, D. F. V. Mondelli, S. Bonaccorso, A. Sim-  
940 mons, A. David, P. Girardi, C. Pariante, R. Murray, and P. Dazzan. Effect of high-  
941 potency cannabis on corpus callosum microstructure. *Psychol Med*, 46(4):841–854,  
942 2015. ISSN 0033-2917. doi: 10.1017/s0033291715002342.
- 943 L. Rovira-Esteban, Z. Péterfi, A. Vikór, Z. Máté, G. Szabó, and N. Hájos. Morphological  
944 and physiological properties of cck/cb1r-expressing interneurons in the basal amygdala.  
945 *Brain Structure and Function*, 222(8):3543–3565, 2017.
- 946 R. Saravia, M. Ten-Blanco, M. Julià-Hernández, H. Gagliano, R. Andero, A. Armario,  
947 R. Maldonado, and F. Berrendero. Concomitant thc and stress adolescent exposure  
948 induces impaired fear extinction and related neurobiological changes in adulthood.  
949 *Neuropharmacology*, 144:345–357, 2019.
- 950 K. G. Schilling, V. Janve, Y. Gao, I. Stepniewska, B. A. Landman, and A. W. Anderson.  
951 Histological validation of diffusion mri fiber orientation distributions and dispersion.  
952 *NeuroImage*, 165:200–221, 2018.
- 953 T. Schnell, A. Kleiman, G. Euphrosyne, J. Daumann, and B. Becker. Increased gray mat-  
954 ter density in patients with schizophrenia and cannabis use: A voxel-based morphome-  
955 tric study using DARTEL. *Schizophr Res*, 138(2-3):183–187, 2012. ISSN 0920-9964.  
956 doi: 10.1016/j.schres.2012.03.021.
- 957 A. D. Schweinsburg, B. C. Schweinsburg, K. L. Medina, T. McQueeny, S. A. Brown, and  
958 S. F. Tapert. The influence of recency of use on fMRI response during spatial working  
959 memory in adolescent marijuana users. *Journal of Psychoactive Drugs*, 42(3):401–412,  
960 2010.
- 961 W. W. Seeley, V. Menon, A. F. Schatzberg, J. Keller, G. H. Glover, H. Kenna, A. L. Reiss,  
962 and M. D. Greicius. Dissociable intrinsic connectivity networks for salience processing  
963 and executive control. *Journal of Neuroscience*, 27(9):2349–2356, 2007.
- 964 S. G. Shollenbarger, J. Price, J. Wieser, and K. Lisdahl. Impact of cannabis use on  
965 prefrontal and parietal cortex gyrification and surface area in adolescents and emerging  
966 adults. *Dev Cogn Neuros-neth*, 16:46–53, 2015. ISSN 1878-9293. doi: 10.1016/j.dcn.  
967 2015.07.004.
- 968 C. Silvestri and V. Di Marzo. The endocannabinoid system in energy homeostasis and  
969 the etiopathology of metabolic disorders. *Cell Metabolism*, 17(4):475–490, 2013.
- 970 T. Singer, H. D. Critchley, and K. Preuschoff. A common role of insula in feelings,  
971 empathy and uncertainty. *Trends in cognitive sciences*, 13(8):334–340, 2009.

- 972 D. M. Small. Taste representation in the human insula. *Brain Structure and Function*,  
973 214(5-6):551–561, 2010.
- 974 L. A. Smith, F. Azariah, V. T. Lavender, N. S. Stoner, and S. Bettiol. Cannabinoids for  
975 nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database*  
976 *of Systematic Reviews*, (11), 2015.
- 977 S. N. Sotiropoulos, S. Jbabdi, J. Xu, J. L. Andersson, S. Moeller, E. J. Auerbach, M. F.  
978 Glasser, M. Hernandez, G. Sapiro, M. Jenkinson, et al. Advances in diffusion MRI  
979 acquisition and processing in the Human Connectome Project. *NeuroImage*, 80:125–  
980 143, 2013.
- 981 N. Stella. Endocannabinoid signaling in microglial cells. *Neuropharmacology*, 56:244–253,  
982 2009.
- 983 E. Tarragon and J. J. Moreno. Role of endocannabinoids on sweet taste perception, food  
984 preference, and obesity-related disorders. *Chemical Senses*, 43(1):3–16, 2017.
- 985 G. Tortoriello, C. V. Morris, A. Alpar, J. Fuzik, S. L. Shirran, D. Calvigioni, E. Keim-  
986 pema, C. H. Botting, K. Reinecke, T. Herdegen, et al. Miswiring the brain:  $\delta$ 9-  
987 tetrahydrocannabinol disrupts cortical development by inducing an scg10/stathmin-2  
988 degradation pathway. *The EMBO journal*, 33(7):668–685, 2014.
- 989 J. Trettel and E. S. Levine. Endocannabinoids mediate rapid retrograde signaling at  
990 interneuron pyramidal neuron synapses of the neocortex. *Journal of neurophysiology*,  
991 89(4):2334–2338, 2003.
- 992 J. M. Tyszka and W. M. Pauli. In vivo delineation of subdivisions of the human amygdaloid  
993 complex in a high-resolution group template. *Human Brain Mapping*, 37(11):  
994 3979–3998, 2016.
- 995 L. Q. Uddin. Salience processing and insular cortical function and dysfunction. *Nature*  
996 *Reviews Neuroscience*, 16(1):55, 2015.
- 997 D. C. Van Essen, S. M. Smith, D. M. Barch, T. E. Behrens, E. Yacoub, K. Ugurbil,  
998 W.-M. H. Consortium, et al. The WU-Minn human connectome project: an overview.  
999 *NeuroImage*, 80:62–79, 2013.
- 1000 H. H. van Hell, M. G. Bossong, G. Jager, G. Kristo, M. J. van Osch, F. Zelaya, R. S. Kahn,  
1001 and N. F. Ramsey. Evidence for involvement of the insula in the psychotropic effects of  
1002 thc in humans: a double-blind, randomized pharmacological mri study. *International*  
1003 *Journal of Neuropsychopharmacology*, 14(10):1377–1388, 2011.

- 1004 N. D. Volkow, R. D. Baler, W. M. Compton, and S. R. Weiss. Adverse health effects of  
1005 marijuana use. *New England Journal of Medicine*, 370(23):2219–2227, 2014.
- 1006 N. D. Volkow, A. J. Hampson, and R. D. Baler. Don’t worry, be happy: endocannabinoids  
1007 and cannabis at the intersection of stress and reward. *Annual Review of Pharmacology  
1008 and Toxicology*, 57:285–308, 2017.
- 1009 S. I. Vrieze. Model selection and psychological theory: a discussion of the differences  
1010 between the akaike information criterion (aic) and the bayesian information criterion  
1011 (bic). *Psychological methods*, 17(2):228, 2012.
- 1012 K. K. Watson, T. K. Jones, and J. M. Allman. Dendritic architecture of the von Economo  
1013 neurons. *Neuroscience*, 141(3):1107–1112, 2006.
- 1014 R. R. Wetherill, Z. Fang, K. Jagannathan, A. Childress, H. Rao, and T. R. Franklin.  
1015 Cannabis, cigarettes, and their co-occurring use: Disentangling differences in default  
1016 mode network functional connectivity. *Drug Alcohol Depen*, 153:116–123, 2015. ISSN  
1017 0376-8716. doi: 10.1016/j.drugalcdep.2015.05.046.
- 1018 P. F. Whiting, R. F. Wolff, S. Deshpande, M. Di Nisio, S. Duffy, A. V. Hernandez,  
1019 J. C. Keurentjes, S. Lang, K. Misso, S. Ryder, et al. Cannabinoids for medical use: a  
1020 systematic review and meta-analysis. *JAMA*, 313(24):2456–2473, 2015.
- 1021 H. Wickham. The tidyverse. *R package ver. 1.1*, 1, 2017.
- 1022 K. Wiech, C.-s. Lin, K. H. Brodersen, U. Bingel, M. Ploner, and I. Tracey. Anterior insula  
1023 integrates information about salience into perceptual decisions about pain. *Journal of  
1024 Neuroscience*, 30(48):16324–16331, 2010.
- 1025 S. Y. Yi, B. R. Barnett, M. Torres-Velázquez, Y. Zhang, S. A. Hurley, P. A. Rowley,  
1026 D. Hernando, and J.-P. J. Yu. Detecting microglial density with quantitative multi-  
1027 compartment diffusion mri. *Frontiers in neuroscience*, 13:81, 2019.
- 1028 M. Yücel, A. Zalesky, M. J. Takagi, E. Bora, A. Fornito, M. Ditchfield, G. F. Egan,  
1029 C. Pantelis, and D. I. Lubman. White-matter abnormalities in adolescents with long-  
1030 term inhalant and cannabis use: a diffusion magnetic resonance imaging study. *J  
1031 Psychiatr Neurosci*, 35(6):409–412, 2010. ISSN 1180-4882. doi: 10.1503/jpn.090177.
- 1032 A. Zalesky, N. Solowij, M. Yücel, D. I. Lubman, M. Takagi, I. H. Harding, V. Lorenzetti,  
1033 R. Wang, K. Searle, C. Pantelis, et al. Effect of long-term cannabis use on axonal fibre  
1034 connectivity. *Brain*, 135(7):2245–2255, 2012.
- 1035 H. Zhang, P. A. Yushkevich, D. C. Alexander, and J. C. Gee. Deformable registration  
1036 of diffusion tensor mr images with explicit orientation optimization. *Medical image  
1037 analysis*, 10(5):764–785, 2006.

- 1038 H. Zhang, B. B. Avants, P. A. Yushkevich, J. H. Woo, S. Wang, L. F. McCluskey,  
1039 L. B. Elman, E. R. Melhem, and J. C. Gee. High-dimensional spatial normalization of  
1040 diffusion tensor images improves the detection of white matter differences: an example  
1041 study using amyotrophic lateral sclerosis. *IEEE transactions on medical imaging*, 26  
1042 (11):1585–1597, 2007.
- 1043 H. Zhang, T. Schneider, C. A. Wheeler-Kingshott, and D. C. Alexander. Noddi: prac-  
1044 tical in vivo neurite orientation dispersion and density imaging of the human brain.  
1045 *NeuroImage*, 61(4):1000–1016, 2012.
- 1046 S. Zhang, H. Peng, R. J. Dawe, and K. Arfanakis. Enhanced ICBM diffusion tensor  
1047 template of the human brain. *NeuroImage*, 54(2):974–984, 2011.